Immune Response to a Hepatitis B DNA Vaccine in Aotus Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration

Table 1 Summary of experimental groups of Aotus monkeys immunized against HBsAg

Group	Gender	Immunogen ^a	Formulation ^b	Delivery Route and Method ^c
1	1 F, 3 M	DNA	Saline	IM, needle and syringe, 4 sites
2	1 F, 3 M	DNA	Saline	IM, Biojector, 4 sites
3	3 F, 1 M	DNA	Liposome	IM, needle and syringe, 4 sites
4	1 F, 3 M	DNA	Liposome	IM, Biojector, 4 sites
5	2 F, 2 M	DNA	Saline	ID, needle and syringe, 4 sites
6	1 F, 3 M	DNA	Saline	IM, Biojector and ID, needle and syringe, 2 sites each
7	4M	DNA	E. coli DNA	IM, needle and syringe, 4 sites
8	3 F, 1 M	DNA	E. coli DNA	ID, needle and syringe, 4 sites
9	3 F, 1 M	Engerix-B	N/A	IM, needle and syringe, 1 site

^aDNA (pCMV_A-S, 400 µg) was given at 0 and 8 weeks to all monkeys except group 9. All monkeys received Engerix-B (10 µg HBsAg + alum) at 16 weeks.
^bDNA was dissolved in saline or was complexed with a cationic liposome (CellFECTIN) at a 10:1 w/w DNA:lipid ratio. DNA formulated with E.coli DNA was dissolved in saline. N/A = not applicable.
^cSites for IM were bilateral deltoid and quadriceps. Sites for ID were over lower back.

ISSN: 1528-3658